CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nuvo Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nuvo Pharmaceuticals Inc
6733 Mississauga Rd, Suite 800
Phone: (905) 673-6980p:905 673-6980 MISSISSAUGA, ON  L5N 6J5  Canada Fax: (905) 673-1842f:905 673-1842
On 3/14/2023, the Company was acquired by Searchlight Pharma Inc.
This company is no longer actively traded on any major stock exchange.
Business Summary
Nuvo Pharmaceuticals Inc. is a Canada-based healthcare company. The Company's products target several therapeutic areas, including pain, allergy, neurology, and dermatology. It operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment offers products with promotional efforts, such as Blexten, Cambia, Suvexx, and NeoVisc, as well as mature products. The Production and Service Business segment includes the sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the licensing of intellectual property and ongoing royalties from licensing agreements with partners.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Robert P.Harris 5/1/2021 5/11/2017
President, Chief Executive Officer Jesse F.Ledger 11/21/2017 4/4/2016
Independent Vice Chairman of the Board John C.London 1/1/2022 12/31/2018
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ZARS Pharma, Inc. 1455 West 2200 South, Salt Lake UT United States

Business Names
Business Name
Dimethaid (UK) Ltd.
Dimethaid Immunology Inc.
Dimethaid Research Inc.
12 additional Business Names available in full report.

General Information
Number of Employees: 100 (As of 12/31/2021)
Outstanding Shares: 11,388,000 (As of 9/30/2022)
Shareholders: 121
Stock Exchange: TSE
Fax Number: (905) 673-1842


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 15, 2024